Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 266.25 -2.7 (-1%) Market Cap: 34.34 Bil Enterprise Value: 33.21 Bil PE Ratio: 0 PB Ratio: 1,065.00 GF Score: 78/100

Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 01:20PM GMT
Release Date Price: $156.63 (+6.80%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everyone, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team.

Our next presenting company is Alnylam. And speaking on behalf of the company, we have CEO, John Maraganore. Before I turn it over to John, I just wanted to highlight for those listeners on the webcast to feel free to submit a question via the ask-a-question feature in the portal. John?

John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

Thanks, Anupam. It's great to be here. It's especially great to put 2020 and even this past week behind us now and to be in 2021.

Despite last year's adversities, Alnylam actually had one of its strongest years ever. And I'm so proud of our Alnylam employees who persevered with their challenge-accepted spirit and a commitment to the patients we serve. For example, we started 2020 with 2 products, 6

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot